Organovo's Management Team
Management Team
 |
|
Keith Murphy, Chief Executive Officer and President, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has 16 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. His 10 years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a BS in Chemical Engineering from MIT, and is an alumnus of the UCLA Anderson School of Management. |
 |
|
Gabor Forgacs, Scientific Founder and Chief Scientific Officer is the George H. Vineyard Professor of Biological Physics at the University of Missouri. He developed Organovo’s breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant. Prof. Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press. He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980’s from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. |
Board of Directors (in addition to above)
 |
|
Robert Baltera, Jr. MS, MBA, Chief Executive Officer of Amira Pharmaceuticals Bob is a seasoned pharmaceutical industry executive, who acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. In his role leading Amira Pharmaceuticals, he has been instrumental in focusing the company’s development efforts, strengthening and developing its pipeline and forging key collaborations with partners such as GlaxoSmithKline. Before becoming Amira’s CEO, Bob held a number of senior management positions at Amgen, the last being vice president of corporate and contract manufacturing.
He successfully used his collective experience to serve as team leader responsible for the approval of Kineret™ in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen.
Bob has a master’s of business administration from the Anderson School at UCLA and earned his bachelor’s degree in microbiology and a master’s degree in genetics from The Pennsylvania State University.
|
 |
|
Andras Forgacs, MBA, Managing Director, Richmond Management In his role at Richmond, Andras focuses on the day-to-day management of the portfolio and sourcing new investment opportunities. Prior to Richmond, Andras was a consultant in the New York office of McKinsey & Company advising global financial institutions and private equity/venture capital firms. Andras began his career with Citigroup as an investment banker in the Financial Strategy Group, and helped found the client-facing E-commerce Group.
Andras holds an MBA from the Wharton School of Business and a Bachelor of Arts with honors from Harvard University. Andras also serves as a Corporate Leader with the Council on Foreign Relations.
|
|
